All News
Filter News
Found 806,088 articles
-
Polymedco announces US FDA clearance of the PATHFAST high-sensitivity cardiac troponin I (hs-cTnI-II) test as an aid in the diagnosis of myocardial infarction
3/27/2024
The PATHFAST hs-cTnI-II, a breakthrough high-sensitivity troponin assay developed for the PATHFAST Biomarker Analyzer, received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
-
Biopharmaceuticals Contract Manufacturing Market Size To Hit USD 31.92 Bn By 2032
3/27/2024
According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.
-
Clinical Microbiology Market is Experiencing Significant Growth
3/27/2024
The global clinical microbiology market size was estimated at around USD 4.58 billion in 2023 and it is projected to hit around USD 7.73 billion by 2033.
-
Thermo Fisher Scientific Announces a New In-line Metrology Solution to Improve Battery Safety and Performance
3/27/2024
To address the needs of the rapidly growing battery market, Thermo Fisher Scientific today introduced the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer, which delivers full-width electrode mass loading measurement and provides battery manufacturers with the data needed to make better, safer batteries, more efficiently.
-
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
3/27/2024
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
-
Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope
3/27/2024
Synaptive Medical Inc. has received 510(k) clearance from the Food and Drug Administration (FDA) for its Near-Infrared fluorescence visualization module, Modus IR, adding to the existing fluorescence offering on its 4K 3D robotic exoscope, Modus X.
-
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
3/27/2024
Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating IAM1363, a selective and brain-penetrant inhibitor of HER2 signaling for the treatment of HER2-driven cancers.
-
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
3/27/2024
Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT) today announced the completion of a Phase 1 hepatic impairment study with denifanstat, a selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
-
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
3/27/2024
Innovent Biologics, Inc. announces that the first participant has been successfully dosed with IBI310 in combination with sintilimab in a randomized, controlled, multicenter Phase 3 clinical trial, for resectable MSI-H/dMMR[1] colon cancer neoadjuvant therapy.
-
Coave Therapeutics to Present at Upcoming Conferences - March 27, 2024
3/27/2024
Coave Therapeutics, a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences.
-
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
3/27/2024
Ludwig Enterprises, Inc is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma, an incurable brain cancer.
-
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
3/27/2024
Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid products for a wide range of applications, including wound care and dermatological conditions, highlights the safety advantages of its Microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products.
-
Synthego Announces CEO Transition to Focus on Enabling CRISPR Therapeutics
3/27/2024
Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately.
-
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
3/27/2024
Pyxis Oncology, Inc. announced that it has completed the sale of its rights to royalties from the commercialization of Beovu® and another asset to Novartis for a one-time cash payment of $8 million.
-
Theralase(R) Release's 4Q2023 Interim Financial Statements
3/27/2024
Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements.
-
Linear Health Sciences Publishes Whitepaper Examining IV Dislodgement
3/27/2024
Linear Health Sciences announced the publication of a new whitepaper on accidental dislodgement of IV catheter lines.
-
KeifeRx Announces the Appointments of Dan Feehan and Alison Finger to Board of Directors
3/27/2024
KeifeRx announces the appointments of Dan Feehan and Alison Finger to its Board of Directors.
-
Pluri Inc. Announces 1-for-8 Reverse Share Split
3/27/2024
Pluri Inc. announced that a reverse share split of the Company’s issued and outstanding common shares, par value $0.00001 per share at a ratio of 1-for-8 is expected to be implemented at market open on April 1, 2024.
-
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
3/27/2024
Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that it has entered into a Restructuring Support Agreement with certain funds managed by Highbridge Capital Management, LLC, the Company’s principal lender.
-
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
3/27/2024
Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.